论文部分内容阅读
目的观察早期服用开博通治疗急性心肌梗塞的近期效果。资料与方法２０１例急性心肌梗塞症状后２４小时内入院且无明显低血压患者，自入院开始后在接受常规治疗基础上，１２８例加服开博通（治疗组），６０例加服安慰剂（对照组），均治疗４周。结果治疗组中前壁梗塞患者的室性心律失常、心力衰竭、梗塞延展发生率、４周病死率以及１年院外猝死率均低于对照组前壁梗塞患者，而下壁梗塞患者无此差异；治疗组中下壁梗塞患者并发房室传导阻滞者高于对照组下壁梗塞患者，而前壁梗塞患者无此差异。结论开博通能降低前壁梗塞患者的住院期重要并发症及早期病死率，且能降低１年院外猝死率。
Objective To observe the recent effect of Kaibutong in treating acute myocardial infarction. Materials and Methods In 201 cases of acute myocardial infarction symptoms within 24 hours after admission and no obvious hypotension, since the admission started on the basis of conventional treatment, based on 128 cases plus open Broadcom (treatment group), 60 plus placebo (Control group), were treated for 4 weeks. Results The incidence of ventricular arrhythmias, heart failure, infarct extension, 4-week mortality and 1-year sudden death in hospital were lower in the treatment group than those in the control group, but not in the infarcted patients ; In the treatment group, the patients with inferior wall infarction complicated by atrioventricular block were higher than the control group with inferior wall infarction, while there was no difference in the anterior wall infarction patients. Conclusion Kaibutong can reduce the important complications of hospital stay and early mortality in patients with anterior wall infarction, and can reduce 1-year rate of out-of-hospital sudden death.